In lung adenocarcinomas loss of PTEN expression in EGFR-mutant cells correlates with increased drug resistance [21], but the rarity of the deletion observed entails the hypothesis that loss of expression is not due to a genomic alteration of PTEN. This evidence concerns the gene PTEN and lung adenocarcinoma.